Related Experiment Video
Updated: Feb 24, 2026
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
Rethinking Schistosomiasis Vaccine Development: Synthetic Vesicles
Moses Egesa1, Karl F Hoffmann2, Cornelis H Hokke3
1Department of Medical Microbiology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda; Medical Research Council/Uganda Virus Research Institute Uganda Research Unit on AIDS, Entebbe, Uganda.
No vaccine currently exists for schistosomiasis. Researchers propose exploring novel antigens from the schistosomulum stage and developing synthetic vesicles for effective vaccine delivery and adjuvant strategies against this parasitic disease.
Area of Science:
- Parasitology
- Immunology
- Vaccine Development
Background:
- Schistosomiasis remains a significant global health burden with no existing vaccine.
- Limited progress in clinical trials for Schistosoma vaccine candidates necessitates exploring new avenues.
Purpose of the Study:
- To identify and evaluate unexplored antigens from the vulnerable schistosomulum stage of Schistosoma as potential vaccine candidates.
- To propose the development of synthetic vesicles as a novel delivery system and adjuvant for schistosomulum-based vaccines.
Main Methods:
- Antigen discovery from the schistosomulum stage.
- Design and formulation of synthetic vesicles for vaccine delivery.
- Evaluation of immunogenicity and efficacy of proposed vaccine candidates (conceptual).
Main Results:
- Identification of promising, unexplored antigens from the schistosomulum stage.
- Conceptualization of synthetic vesicles as a dual-purpose delivery vehicle and adjuvant.
Conclusions:
- Unexplored antigens from the schistosomulum stage represent a viable strategy for developing a schistosomiasis vaccine.
- Synthetic vesicles offer a novel platform for enhancing the immunogenicity and delivery of schistosomiasis vaccine candidates.
